Summary: “Evidence suggests that chronic neuroinflammation has an important role in the pathogenesis of Alzheimer disease. However, in a new clinical trial, the tetracycline antibiotic minocycline, which has anti-inflammatory properties, failed to delay disease progression in individuals with mild Alzheimer disease.”

Gyengesi E and Münch G: In search of an anti-inflammatory drug for Alzheimer disease. Nature Rev Neurol. [Epub ahead of print, Jan 9, 2020; doi: 10.1038/s41582-019-0307-9].

This entry was posted in Uncategorized. Bookmark the permalink.

Comments are closed.